Bijoy Hans Standalone September 2021 Net Sales At Rs 0.06 Crore, Down 57.57% Y-o-Y

Bijoy Hans reports standalone net loss of Rs 0.06 crore in the September 2021 quarter

Bijoy Hans Standalone June 2021 Net Sales At Rs 0.11 Crore, Down 23.68% Y-o-Y

Bijoy Hans reports standalone net loss of Rs 0.04 crore in the March 2021 quarter

Bijoy Hans reports standalone net loss of Rs 0.02 crore in the December 2020 quarter

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

The Company offer various pharmaceutical formulations such as tablets, capsules, syrups, suspension and powders, focusing on segments such as ANTIBIOTICS, COUGH/COLD/ALLERGY, H-1RECEPTOR ANTAGONIST (ANTIULCERANT), NUTRACEUTICALS and NSAIDS

Bijoy Hans Ltd